| |
-Packed Cell Volume
-PACP
-Pamelor®
-PANCA
-Pancreatic Polypeptide (PANPP)
-PAP
-Pap Smear
-Pap Test
-Pap Test with HPV Reflex Testing
-Papanicolaou Smear
-Paracentesis Fluid Cytology
-Parainfluenza Virus Antibody Profile (PAVA)
-Parainfluenza Virus Culture
-Parasite Identification (PID)
-Parasites, Stool
-Parasitology Examination for Malaria
-Parathyroid Hormone Related Peptide (PTHRP)
-Parathyroid Hormone, C-Terminal (CTPTH)
-Parathyroid Hormone, Intact, Profile (INPHP)
-Parathyroid Hormone, Intact, Serum (INPH)
-Parietal Cell Antibody
-Parietal Cell Autoantibody (APCA)
-Partial Thromboplastin Time (APTT) Profile (PTTP)
-Partial Thromboplastin Time, Activated (APTT), Plasma (PTT)
-Parvovirus B19 Antibody Profile (PARV)
-PAS (PAS)
-PAS Stain
-Pathologic Examination
-Pathology
-Pb, Blood
-PCP
-PCV
-6PD
-Pediatric Allergen Profile
-Pelvic Washing Cytology
-Pemphigoid
-Pemphigus
-Pemphigus Antibodies
-Pentobarbital (PENTO)
-Pericardial Fluid Cytology
-Pericardiocentesis Fluid Cytology
-Peritoneal Dialysate
-Peritoneal Fluid
-Peritoneal Fluid
-Peritoneal Fluid Culture
-Peritoneal Fluid Cytology
-Peritoneal Lavage Profile (DPL)
-Peritoneal Washing Cytology
-Peroxidase Anti-Peroxidase
-Peroxisomal Panel
|
|
|
|
Print |
| 6PD |
| |
| See Glucose-6-Phosphate Dehydrogenase |
Print |
| ProfileCardiolipin Antibodies |
| |
| See Cardiolipin Autoantibody Profile |
Print |
| Packed Cell Volume |
| |
| See Hematocrit, Whole Blood |
Print |
| PACP |
| |
| See Acid Phosphatase, Prostatic |
Print |
| Pamelor® |
| |
| See Nortriptyline |
Print |
| PANCA |
| |
| See Neutrophil Cytoplasmic Autoantibody Profile |
Print |
| Pancreatic Polypeptide |
| |
| CPT: |
83519 |
| |
| Methodology: |
Radioimmunoassay (RIA) |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
3 mL plasma |
| |
| Container: |
2 Lavender top (EDTA) tubes |
| |
| Collection: |
Overnight fast (8 hour minimum) required. |
| |
| Special Instructions and/or Comments: |
•Must be processed and frozen immediately •Centrifuge, transfer to plastic aliquot tube and freeze. Once frozen, transport specimen submerged in dry ice. |
| |
| Reference Range: |
0-19 years:.................Not established 20-29 years:...............< 228 pg/mL 30-39 years:.............. < 249 pg/mL 40-49 years:.............. < 270 pg/mL 50-59 years:.............. < 291 pg/mL 60-69 years:.............. < 312 pg/mL 70-79 years: ............. < 332 pg/mL >80 years:..................Not established |
| |
| Clinical Utility: |
| Useful for detection of pancreatic endocrine tumors and assessment of vagal nerve function after meal or sham feeding. |
| |
Print |
| PAP |
| |
| See Acid Phosphatase, Prostatic |
| See Histopathology,Immunoperoxidase Procedures |
Print |
| Papanicolaou Smear |
| |
| See Cytolopathology,ThinPrep® Pap Test and ThinPrep® plus Imager |
Print |
| Pap Smear |
| |
| See Cytolopathology,ThinPrep® Pap Test and ThinPrep® plus Imager |
Print |
| Pap Test |
| |
| See Cytolopathology,ThinPrep® Pap Test and ThinPrep® plus Imager |
Print |
| Pap Test with HPV Reflex Testing |
| |
| See Cytolopathology,ThinPrep® Pap Test and ThinPrep® plus Imager |
Print |
| Paracentesis Fluid Cytology |
| |
| See Cytopathology, Fluid |
Print |
| Parainfluenza Virus Antibody Profile |
| |
| Includes: |
Parainfluenza Virus 1, 2 and 3 antibodies |
| |
| CPT: |
86790 (x3) |
| |
| Methodology: |
Complement Fixation |
| |
| Testing Schedule: |
Routine, Monday-Friday |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
< 1:8...........No antibody detected. > 1:8...........Antibody detected. NOTE Compare acute and convalescent titers for greatest diagnostic value. A four fold or greater increase in titer between acute and convalescent specimens confirms the diagnosis of recent infection. |
| |
| Clinical Utility: |
| Single titers of > 1.64 are indicative of recent infection. Titers of 1:8 to 1:32 may be indicative of either past or recent infection, since CF antibody levels persist for only a few months. A four fold increase or greater in titer between acute and convalescent specimens confirms the diagnosis. After initial infection, antibody responses at a later date are often heterotypic and exhibit cross reactivity with other paramyxoviruses (e.g. mumps) |
| |
Print |
| Parainfluenza Virus Culture |
| |
| See Culture, Viral, Respiratory |
Print |
| Parasite Identification |
| |
| Includes: |
Examination and identification of parasites or parasite-like specimens extracted from fecal or other specimens. |
| |
| CPT: |
87169 |
| |
| Alternate Name: |
•Ascaris; Beef Tapeworm; Diphyllobothrium latum; •Echinococcus; Enterobius; Fish Tapeworm; Gross •Worm Identification; Hydatid Larva; Nematode •Identification; Ova and Parasite, Gross Worm •Identification; Pork Tapeworm; Roundworm •Identification, Taenia sp; Tapeworm Identification See also •Arthropod Identification (Ticks, Fleas, Lice) •Pinworm Identification •Ova and Parasites, Stool |
| |
| Methodology: |
Microscopic Identificiation |
| |
| Testing Schedule: |
Routine, Monday-Friday only |
| |
| Report Available: |
1-3 days |
| |
| Specimen Requirements: |
| Container: |
Clean, dry container containing parasite |
| |
| Collection: |
Small amount of saline or 10% Formalin may be added to container to cover worm. |
| |
| Special Instructions and/or Comments: |
| Maintain specimen at room temperature. |
| |
| Clinical Utility: |
| Parasitic diseases around the world have one of the highest morbidity and mortality rates.Proper diagnosis of parasitic infections relies on proper collection, transport and identification of parasites in specimens. |
| |
Print |
| Parasites, Stool |
| |
| See Ova and Parasites, Stool |
Print |
| Parasitology Examination for Malaria |
| |
| See Blood Parasites |
Print |
| Parathyroid Hormone, C-Terminal |
| |
| Includes: |
NOTE This assay is a substitution for the “Parathyroid Hormone, Mid-Molecule (PTH, Mid-Molecule)” assay which has been discontinued. • Parathyroid Horomone, C terminal • Calcium, total |
| |
| CPT: |
83970, 82310 |
| |
| Alternate Name: |
C-Terminal PTH |
| |
| Methodology: |
Radioimmunoassay (RIA); Spectrophotometry |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
| Centrifuge, transfer to plastic aliquot tube and freeze. Once frozen, transport specimen submerged in dry ice. |
| |
| Reference Range: |
PTH, C-Terminal..................... < 0.9ng/mL Calcium: • < 2 years:.......................7.6 -11mg/dL • < 19 years......................8.4 -10.5 mg/dL • 19 years & older............8.7 -10.4 mg/dL |
| |
| Clinical Utility: |
| Useful for clinical assessment of parathyroid gland dysfunction and other disorders of calcium homeostasis. As renal function deteriorates in patients with kidney disease, the clearance of C-Terminal PTH (which is excreted only by the kidney) significantly decreases and its half-life in circulation is prolonged, resulting in strikingly high C-Terminal PTH concentrations even in the absence of parathyroid disase. |
| |
Print |
| Parathyroid Hormone, Intact, Profile |
| |
| Includes: |
Calcium Creatinine Intact PTH Phosphorus |
| |
| CPT: |
82310, 82565, 83970, 84100 |
| |
| Alternate Name: |
Intact Parathyroid Hormone Profile |
| |
| Methodology: |
See individual test listings |
| |
| Testing Schedule: |
Routine, STAT testing available 0600-2100 |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
•Testing must be performed within 4 hours of collection. •If delay in transport, centrifuge specimen, transfer serum to plastic aliquot tube and refrigerate for up to 48 hours. |
| |
| Reference Range: |
| See individual test listings |
| |
| Critical Values: |
| See individual test listings |
| |
| Clinical Utility: |
| Useful in aiding and assessing the following disorders Primary Hyperparathyroidism, Hypoparathyroidism and Non-Parathyroid Hypercalemia. |
| |
Print |
| Parathyroid Hormone, Intact, Serum |
| |
| CPT: |
83970 |
| |
| Alternate Name: |
Intact Parathyroid Hormone; Intact PTH |
| |
| Methodology: |
Direct Chemilumenescence |
| |
| Testing Schedule: |
Routine, STAT testing available 0600-2100 |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
•Testing must be performed within 4 hours of collection. •If delay in transport, centrifuge specimen, transfer serum to plastic aliquot tube and refrigerate for up to 48 hours. |
| |
| Reference Range: |
| 14.0-72.0 pg/mL |
| |
| Clinical Utility: |
| Useful in aiding and assessing the following disorders: Primary Hyperparathyroidism, Hypoparathyroidism and Non-Parathyroid Hypercalemia. |
| |
Print |
| Parathyroid Hormone Related Peptide |
| |
| CPT: |
82397 |
| |
| Alternate Name: |
• PTH Related Protein • PTHRP, Parathroid Hormone Related Protein |
| |
| Methodology: |
Immunochemiluminometric Assay (ICMA) |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL plasma |
| |
| Container: |
Prechilled lavender top (EDTA) tube CollectionFasting patient preferred. |
| |
| Special Instructions and/or Comments: |
•Transport to the laboratory immediately. •Centrifuge, transfer to plastic aliquot tube and freeze. Once frozen, transport specimen submerged in dry ice. |
| |
| Reference Range: |
| <2.0 pmol/L |
| |
| Clinical Utility: |
Useful for, Diagnosis of HHM ( Humoral hypercalcemia of malignancy) in patients with hypercalcimia and nonelevated PTH. When a patient with HHM has an increased value, the test is useful to monitor treatment |
| |
Print |
| Parietal Cell Antibody |
| |
| See Parietal Cell Autoantibody |
Print |
| Parietal Cell Autoantibody |
| |
| Includes: |
•Parietal Cell Autoantibody •Reflexed when appropriate Quantitative titer on positive screens |
| |
| CPT: |
86255,Reflexed when appropriate 86256 |
| |
| Alternate Name: |
Antibody to Gastric Parietal Cells; Anti-Parietal Cell Antibody; APCA; Parietal Cell Antibody |
| |
| Methodology: |
Indirect Fluorescent Antibody (IFA) |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
3-5 days (may be extended if further dilutions required) |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Reference Range: |
| Negative titer <1:20 |
| |
| Clinical Utility: |
| Detects autoantibodies useful in the differential diagnosis of pernicious anemia. |
| |
Print |
| Partial Thromboplastin Time, Activated (APTT), Plasma |
| |
| CPT: |
85730 |
| |
| Alternate Name: |
Activated Partial Thromboplastin Time; APTT ; PTT |
| |
| Methodology: |
HNL: Mechanical Clot Detection LPP: Photo Optical Detection |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL citrated plasma |
| |
| Container: |
Full blue top (sodium citrate) tube |
| |
| Special Instructions and/or Comments: |
Non-Heparinized Patients 1. Unopened (capped) tubes, uncentrifuged, or centrifuged stored at 18-24C (room temperature) and tested within 24 hours are accepted. 2. If testing can not be completed within 24 hours, aliquot and freeze plasma according to the special handling instructions for coagulation studies found on page 3.11 of the Handbook. Heparinized Patients 1. Specimen must be centrifuged within 1 hour of collection. 2. If testing can not be completed within 24 hours, aliquot and freeze plasma according to the special handling instructions for coagulation studies found on page 3.11 of the Handbook. |
| |
| Reference Range: |
HNL..........21.6-35.6 seconds* LPP........... 22.9-34.5 seconds* Suggested HNL therapeutic range with anticoagulation with unfractionated heparin. • For venous thrombosis/embolish: 65-95 seconds • For acute coronary syndrome: 55-80 seconds • Concurrent with thrombolytic therapy: 45-65 seconds * Range value varies with reagent lot |
| |
| Critical Values: |
HNL.............>95.0 seconds LPP...............>42.0 seconds* *Range/value varies with reagent lot. |
| |
| Clinical Utility: |
| Used in the evaluation of the intrinsic coagulation system, coagulation disorders and deficiencies.Also used in monitoring heparin therapy. |
| |
Print |
| Partial Thromboplastin Time (APTT) Profile |
| |
| Includes: |
• PTT • PTT mixing study (immediate and incubated) when appropriate • Thrombin Time (TT) reflexed when appropriate • Reptilase Time (REPTL) reflexed when appropriate |
| |
| CPT: |
85730, Reflexed when appropriate, 85732(X2), 85670, 85635 |
| |
| Alternate Name: |
PTT mixing study; PTT Profile |
| |
| Methodology: |
Mechanical Clot Detection |
| |
| Testing Schedule: |
Routine, Monday-Friday only |
| |
| Report Available: |
2-3 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL citrated plasma |
| |
| Container: |
4 full Blue top (sodium citrate) tubes |
| |
| Collection: |
See special handling instructions for “Coagulation Studies”, listed under Specimen Collection, Preparation, and Handling Section |
| |
| Special Instructions and/or Comments: |
• Testing is contraindicated for patients on heparin or Coumadin therapy. • Transport to the laboratory immediately. • If testing cannot be performed within 4 hours of collection, platelet pour plasma must be prepared prior to freezing. • Immediately centrifuge specimens at 1700 to 2000 g for 10 minutes • Remove the plasma and dispense into plastic aliquot tube. Spin aliquot for 10 minutes. • Remove the plasma and dispense into another plastic aliquot tube. Spin new aliquot for 10 minutes. Transfer plasma into 8 aliquot tubes and freeze. • Once frozen, specimens should be submerged in dry ice for transport. |
| |
| Reference Range: |
| See report |
| |
| Critical Values: |
PTT >95.0 seconds* * Value varies with reagent lot |
| |
| Clinical Utility: |
| A PTT mixing study can differentiate between a coagulation factor deficiency or the presence of an inhibitor. |
| |
Print |
| Parvovirus B19 Antibody Profile |
| |
| Includes: |
IgG and IgM Antibodies |
| |
| CPT: |
86747 (x2) |
| |
| Methodology: |
Enzyme Immunoassay (EIA) |
| |
| Testing Schedule: |
Routine, 1 time per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
Volume1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
•IgG :........................< 0.9 •IgM :.......................< 0.9 |
| |
| Clinical Utility: |
| Useful for diagnosing recent parvovirus infection (IgM) Assessing past infection (e.g., screening pregnant women) and immunity to parvovirus infection (IgG) |
| |
Print |
| PAS Stain |
| |
| See Periodic Acid Schiff Stain |
Print |
| Pathologic Examination |
| |
| See Histopathology |
Print |
| Pathology |
| |
| See Histopathology |
Print |
| Pb, Blood |
| |
| See Lead, Blood |
Print |
| PCP |
| |
| See Phencyclidine |
Print |
| PCV |
| |
| See Hematocrit, Whole Blood |
Print |
| Pediatric Allergen Profile |
| |
| See Allergen Profile, Pediatric |
Print |
| Pelvic Washing Cytology |
| |
| See Cytopathology, Fluid |
Print |
| Pemphigoid |
| |
| See Skin Autoantibody Profile |
Print |
| Pemphigus |
| |
| See Skin Autoantibody Profile |
Print |
| Pemphigus Antibodies |
| |
| See Histopathology, Skin Biopsy, Immunofluorescence |
Print |
| Pentobarbital |
| |
| CPT: |
82205 |
| |
| Methodology: |
Gas Chromatography (GC) |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL serum |
| |
| Container: |
Red top tube, no serum separator |
| |
| Reference Range: |
•Therapeutic...........1-5 .µg/mL •Treatment of intracranial pressure with supportive therapy Children.......20-30 .µg/mL Adults..........25-35 µg/mL |
| |
| Clinical Utility: |
Useful for monitoring therapy and assessing toxicity. Percent Saturation |
| |
Print |
| Pericardial Fluid Cytology |
| |
| See Cytopathology, Fluid |
Print |
| Pericardiocentesis Fluid Cytology |
| |
| See Cytopathology, Fluid Periodic Acid Schiff Stain |
Print |
| PAS |
| |
| CPT: |
88313 |
| |
| Alternate Name: |
PAS Stain |
| |
| Methodology: |
Manual |
| |
| Testing Schedule: |
Routine, Monday-Friday only |
| |
| Report Available: |
2-4 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL whole blood OR 2 bone marrow films |
| |
| Container: |
Lavender top (EDTA) tube |
| |
| Collection: |
Routine venipuncture OR bone marrow aspiration |
| |
| Reference Range: |
| Results interpreted by Hematopathologist. |
| |
| Clinical Utility: |
| Used in the evaluation of glycogen, mucopolysaccharides and fungiin tissues. |
| |
Print |
| Peritoneal Dialysate |
| |
| See Culture, CAPD Fluid |
Print |
| Peritoneal Fluid |
| |
| See Peritoneal Lavage Profile |
Print |
| Peritoneal Fluid Culture |
| |
| See Culture, Fluid, Aerobic |
Print |
| Peritoneal Fluid |
| |
| See pH, Body Fluid |
Print |
| Peritoneal Fluid Cytology |
| |
| See Cytopathology, Fluid |
Print |
| Peritoneal Washing Cytology |
| |
| See Cytopathology, Fluid |
Print |
| Peritoneal Lavage Profile |
| |
| Includes: |
•Amylase, Fluid •Bilirubin, Fluid •Cell Count •Particulate Matter |
| |
| CPT: |
82150, 82247, 89050 , 89051 |
| |
| Alternate Name: |
Diagnostic Peritoneal Lavage; Fluid Analysis, Peritoneal Lavage; Peritoneal Fluid |
| |
| Methodology: |
See individual test listings. |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL fluid in each tube |
| |
| Container: |
Red top tube, no serum separator AND lavender top (EDTA) tube |
| |
| Special Instructions and/or Comments: |
The following values are indicative of a blunt trauma •RBC’s ...............>100,000/cumm •WBC’s ..............>500/cumm •Amylase............ >175 Iu/L |
| |
| Reference Range: |
| See Individual test listings |
| |
Print |
| Peroxidase Anti-Peroxidase |
| |
| See Histopathology, Immunoperoxidase Procedures |
Print |
| Peroxisomal Panel |
| |
| See Fatty Acid Profile, Peroxismal (C22-C26) |
Print |
| Pertussis Antibody Profile |
| |
| See Bordetella pertussis Antibody Profile PGH |
| See Alpha Subunit |
Print |
| pH, Body Fluid |
| |
| CPT: |
83986 |
| |
| Alternate Name: |
Body Fluid pH; Dialysis Fluid pH; Drainage pH; Duodenal Aspirate pH; Gastric Aspirate pH; Peritoneal Fluid pH; Thoracentesis Fluid pH; Urine pH |
| |
| Methodology: |
Potentiometry |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL body fluid |
| |
| Container: |
Red top tube, no serum separator |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
| Not established, must be interpreted with clinical findings. |
| |
| Clinical Utility: |
| Used to determine the pH of body fluid to aid in the evaluation of various conditions. |
| |
Print |
| pH, Stool |
| |
| CPT: |
83986 |
| |
| Alternate Name: |
Stool for pH |
| |
| Methodology: |
Manual |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL fresh liquid stool |
| |
| Container: |
Plastic urine container |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
| Not established, must be interpreted with clinical findings. |
| |
| Clinical Utility: |
| Used to evaluate carbohydrate absorption and lower GI tract disorders. |
| |
Print |
| pH, Urine |
| |
| CPT: |
81002 |
| |
| Alternate Name: |
Urine PH |
| |
| Methodology: |
Potentiometry |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
3 mL random urine |
| |
| Container: |
Plastic urine container |
| |
| Collection: |
Freshly voided random urine |
| |
| Reference Range: |
| 4.5-8.0 |
| |
| Clinical Utility: |
| Used as a crude measure of the acid/base balance of the body and to evaluate renal function and renal disorders. |
| |
Print |
| Phencyclidine, Quantitative, Blood |
| |
| Includes: |
Identification and quantitation of phencyclidine in blood. |
| |
| CPT: |
83992 |
| |
| Methodology: |
LC/MS/MS or GC/MS |
| |
| Testing Schedule: |
Once/week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mLs whole blood |
| |
| Container: |
Gray top or lavendar top |
| |
| Reference Range: |
| Not established |
| |
| Clinical Utility: |
| To determine use of phencyclidine. |
| |
Print |
| Phencyclidine, Qualitative, Urine |
| |
| CPT: |
80101 |
| |
| Alternate Name: |
Angel Dust; PCP |
| |
| Methodology: |
Immunoassay (IA) |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL urine |
| |
| Container: |
Plastic urine container |
| |
| Special Instructions and/or Comments: |
| If for forensic or legal purposes, submit specimen with a completed Drug Testing Request and Chain-of-Custody (HNL-53) Form or Blood Alcohol Toxicology Request/Chain-of-Custody (LAB-53) Form. |
| |
| Reference Range: |
None detected. NOTEConfirmation by GC/MS (gas chromatography/mass spectrometry) available upon request.Contact Customer Care 610-402-8170 for instructions. |
| |
| Clinical Utility: |
| A qualitative screen useful for detection of drug abuse/use of phencyclidine.Confirmation of a positive screening result by GC/MS is strongly recommended. |
| |
Print |
| Phenobarbital |
| |
| CPT: |
80184 |
| |
| Methodology: |
Immunoassay (IA) |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Red top or SST tube |
| |
| Reference Range: |
•Therapeutic.......................15-40 .µg/mL •Toxic ................................>40 .µg/mL |
| |
| Clinical Utility: |
| Useful for monitoring therapy and assessing toxicity. |
| |
Print |
| Phencyclidine, Urine, GCMS |
| |
| Includes: |
Identification and quantitation of phencyclidine by GCMS |
| |
| CPT: |
83992 |
| |
| Methodology: |
Gas Chromatography/Mass Spectroscopy (GC/MS) |
| |
| Testing Schedule: |
3 times/week |
| |
| Report Available: |
2-4 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL random urine |
| |
| Container: |
Plastic urine container |
| |
| Special Instructions and/or Comments: |
| If for forensic or legal purposes, submit specimen with a completed Drug Testing Request and Chain-of-Custody (HNL-53) Form or Blood Alcohol Toxicology Request/Chain-of-Custody (LAB-32) Form. |
| |
| Reference Range: |
| None present |
| |
| Clinical Utility: |
| Useful for the detection and positive identification of phencyclidine in urine. |
| |
Print |
| Phenytoin |
| |
| CPT: |
80185 |
| |
| Alternate Name: |
Dilantin®; Diphenylhydantoin |
| |
| Methodology: |
HNL: Endpoint LPP: Turbidimetric rate |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Red top or SST tube |
| |
| Collection: |
I.V.: 2-4 hours after loading dose. Oral: •Peak = 3-9 hours after dose. •Trough = immediately prior to next dose. NOTE Optimal resampling after change in dosage 48 hours. |
| |
| Reference Range: |
| Therapeutic....................10-20 µg/mL |
| |
| Critical Values: |
| >30.0 µg/mL |
| |
| Clinical Utility: |
| Used to measure the amount of phenytoin in the blood and to determine if the drug concentration is within the therapeutic range. |
| |
Print |
| Phenytoin, Free |
| |
| CPT: |
80186 |
| |
| Alternate Name: |
Free Dilantin®; Free Phenytoin |
| |
| Methodology: |
Ultrafiltration, Immunoassay (IA) |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum OR plasma |
| |
| Container: |
Red top tube, no serum separator OR green top (lithium heparin) tube |
| |
| Reference Range: |
| Therapeutic Free1-2µg/mL |
| |
| Clinical Utility: |
The Phenytoin that circulates in blood is 90 % protein bound under normal circumstances.Since neurologic activity and toxicity of Phenytoin are directly related to the unbound fraction of the drug, measurement of the free or unbound drug may be necessary where altered protein binding is possible, such as in hypoalbuminemia, pregnancy, renal or hepatic failure, the elderly or use of concomitant drug therapy. |
| |
Print |
| Philadelphia Chromosome |
| |
| See Chromosome Analysis,Hematological, Bone Marrow |
Print |
| Phos |
| |
| See Phosphorus, Serum |
Print |
| Phosphatase, Alkaline |
| |
| See Alkaline Phosphatase, Total, Serum |
Print |
| Phosphatidylcholine Autoantibody Profile |
| |
| Includes: |
• Phosphatidylcholine IgG Autoantibodies • Phosphatidylcholine IgM Autoantibodies • Phosphatidylcholine IgA Autoantibodies |
| |
| CPT: |
83520 (X3) |
| |
| Alternate Name: |
Phosphatidylcholine IgG, IgM, & IgA Autoantibodies |
| |
| Methodology: |
EIA |
| |
| Testing Schedule: |
1 time/week |
| |
| Report Available: |
7-10 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold Top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
Phosphatidylcholine IgG Autoantibodies......< 10.0 U/mL Phosphatidylcholine IgM Autoantibodies......< 10.0 U/mL Phosphatidylcholine IgA Autoantibodies.......< 10.0 U/mL |
| |
| Clinical Utility: |
| Useful for the detection of antibodies directed at phospholipid epitopes. |
| |
Print |
| Phosphatidyethanolamine Autoantibody |
| |
| Includes: |
Phosphatidyethanolamine IgG Autoantibodies, Phosphatidyethanolaminel IgM Autoantibodies, Phosphatidyethanolamine IgA Autoantibodies |
| |
| CPT: |
83520 (X3) |
| |
| Alternate Name: |
Phosphatidyethanolamine IgG, IgM, & IgA Autoantibodies |
| |
| Methodology: |
EIA |
| |
| Testing Schedule: |
1 time/week |
| |
| Report Available: |
7-10 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mLserum |
| |
| Container: |
Gold Top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
Phosphatidyethanolamine IgG Autoantibodies ........< 10.0 U/mL Phosphatidyethanolamine IgM Autoantibodies ........< 10.0 U/mL Phosphatidyethanolamine IgA Autoantibodies ........ < 10.0 U/mL |
| |
| Clinical Utility: |
| Useful for the detection of antibodies directed at phospholipid epitopes. |
| |
Print |
| Phosphatidylinositol Autoantibody Profile |
| |
| Includes: |
Phosphatidylinositol IgG Autoantibodies, Phosphatidylinositol IgM Autoantibodies, Phosphatidylinositol IgA Autoantibodies |
| |
| CPT: |
83520 (X3) |
| |
| Alternate Name: |
Phosphatidyinositol IgG, IgM, & IgA Autoantibodies |
| |
| Methodology: |
EIA |
| |
| Testing Schedule: |
1 time/week |
| |
| Report Available: |
7-10 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mLserum |
| |
| Container: |
Gold Top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
Phosphatidylinositol IgG Autoantibodies........<10 U/mL Phosphatidylinositole IgM Autoantibodies ..... <10 U/mL Phosphatidylinositole IgA Autoantibodies .......<10 U/mL |
| |
| Clinical Utility: |
| Useful for the detection of antibodies directed at phospholipid epitopes. |
| |
Print |
| Phosphatidylserine Antibodies |
| |
| See Phosphatidylserine Autoantibody Profile |
Print |
| Phosphatidylserine Autoantibody Profile |
| |
| Includes: |
IgG, IgA and IgM Autoantibodies |
| |
| CPT: |
86148 (x3) |
| |
| Alternate Name: |
Anti-Phosphatidylserine Antibody Profile, G/A/M; Phosphatidylserine G/A/M; Phosphatidylserine Antibodies |
| |
| Methodology: |
Enzyme-Linked Immunosorbent Assay (ELISA) |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
3 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
| Centrifuge, transfer to plastic aliquot tube and freede Once frozen, transport specimen submerged in dry ice. |
| |
| Reference Range: |
IgG...................<11 GPS U/mL IgM..................<25 MPS U/mL IgA..................<20 APS U/mL IgG <11 GPS U/mL- Antibody not detected >=11 GPS U/mL – Antibody detected IgA <20 APS U/mL – Antibody not detected >=20 APS U/mL – Antibody detected IgM <25 MPS U/mL -Antibody not detected >=25 MPS U/mL – Antibody detected |
| |
| Clinical Utility: |
| Phosphatidylserine autoantibodies are associated with SLE, lupus-like diseases and the primary antiphospholipid syndrome. Clinical problems are generally related to arterial and deep venous thromboses, recurrent spontaneous abortion, neurological and cardiological manifestations and thrombocytopenia. |
| |
Print |
| Phosphatidylserine G/A/M |
| |
| See Phosphatidylserine Autoantibody Profile |
Print |
| Phospholipid Antibodies |
| |
| See Anti-Phospholipid Antibody Profile |
Print |
| Phospholipid Autoantibodies |
| |
| See Anti-Phospholipid Antibody Profile |
Print |
| Phosphorus, Serum |
| |
| CPT: |
84100 |
| |
| Alternate Name: |
Inorganic Phosphate; Phos Inorganic Phosphorus |
| |
| Methodology: |
HNL Endpoint LPP Bichromatic endpoint |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Reference Range: |
< 15 days:...........5.0-7.8 mg/dL > 15 days...........4.5-6.5 mg/dL > 2 years.............4.5-5.5 mg/dL > 16 years..........2.5-4.5 mg/dL |
| |
| Critical Values: |
<2.0 mg/dL >7.0 mg/dL |
| |
| Clinical Utility: |
| Used in the evaluation of ketoacidosis, malnutrition, conditions that affect the kidneys and gastrointestinal tract, and to evaluate the body’s utilization of calcium. |
| |
Print |
| Phosphorus, UrineRandom |
| |
| CPT: |
84105 |
| |
| Alternate Name: |
Urine Phos; Urine Phosphorus |
| |
| Methodology: |
Endpoint |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL random urine ContainerPlastic urine container Collection Random |
| |
| Special Instructions and/or Comments: |
| and/or CommentsTransport to the laboratory promptly. |
| |
| Reference Range: |
| 20-86 mg/dL |
| |
| Clinical Utility: |
| Use to evaluate phosphorus/calcium balance and phosphorus elimination by the kidneys. |
| |
Print |
| Phosphorus, Urine24-Hour |
| |
| Includes: |
Volume Measurement Collection Period Creatinine, Urine Phosphorus, Urine |
| |
| CPT: |
81050, 84105 |
| |
| Alternate Name: |
Urine Phos; Urine Phosphorus |
| |
| Methodology: |
Endpoint |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
Entire 24-Hour urine collection |
| |
| Container: |
Entire 24-Hour plastic urine container, no preservative |
| |
| Collection: |
24-Hour urine collection See special instructions for “24-Hour Urine Collection”, listed under Specimen Collection, Preparation, and Handling Section |
| |
| Special Instructions and/or Comments: |
| Transport to the laboratory promptly. |
| |
| Reference Range: |
•Creatinine, 24-Hour Urine........... 0.8-2.8 g/24 hours •Phosphorus, 24-Hour Urine.........400-1300 mg/24 hours |
| |
| Clinical Utility: |
| Use to evaluate phosphorus/calcium balance and phosphorus elimination by the kidneys. |
| |
Print |
| Phytanic Acid |
| |
| See Fatty Acid Profile, Peroxismal (C22-C26) |
Print |
| Pinworm Identification |
| |
| CPT: |
87172 |
| |
| Alternate Name: |
Enterobius |
| |
| Methodology: |
Microscopic Identification |
| |
| Testing Schedule: |
Routine, Monday–Friday only |
| |
| Report Available: |
1-3 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 Swube™ OR Scotch® Tape Preparation (clear tape with sticky side down on slide) |
| |
| Collection: |
Touch perianal area with sticky side of Swube™ OR Scotch® tape, early morning prior to bowel movement or bathing, place tape on glass slide, sticky side down. |
| |
| Reference Range: |
| No Pinworm observed. |
| |
| Clinical Utility: |
Pinworm infestation is diagnosed by observing eggs that are deposited around the anus.The eggs are not normally seen in fecal specimens. |
| |
Print |
| Pituitary Gonadotropin |
| |
| See Follicle Stimulating Hormone, Serum |
Print |
| PKU Screen |
| |
| See Newborn Screening, State Mandated |
Print |
| Placental Tissue Examination |
| |
| See Histopathology, Placenta |
Print |
| Plasma Renin Activity |
| |
| See Renin Activity |
Print |
| Plasminogen, Activity |
| |
| CPT: |
85420 |
| |
| Alternate Name: |
Functional Plasminogen |
| |
| Methodology: |
Chromogenic Assay |
| |
| Testing Schedule: |
Routine, 1 time per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL prepared “platelet poor plasma” split equally into 2 plastic aliquot tubes and FROZEN immediately. |
| |
| Container: |
2 Blue top (sodium citrate) tubes |
| |
| Collection: |
See special handling instructions for “Coagulation Studies”, listed under Specimen Collection, Preparation, and Handling Section |
| |
| Special Instructions and/or Comments: |
•Testing is contraindicated for patients on Heparin or Coumadin therapy. •Preparation and submission of “platelet poor plasma” is critical for accurate test performance and interpretation.See collection note above. Causes for rejection •Extended transport time to laboratory •Clotted specimens •Hemolyzed specimens •Blue top sodium citrate tubes insufficiently filled •Aliquots not received frozen on dry ice •Frozen aliquots not clearly identified as “platelet poor plasma” |
| |
| Reference Range: |
| 67% to 134% |
| |
| Clinical Utility: |
| Plasminogen deficiency is associated with detectivefibrinolytic system or hypercoagulable states. |
| |
Print |
| Plasmodium Smear |
| |
| See Blood Parasites |
Print |
| Platelet Aggregatin |
| |
| Includes: |
Evaluation of Platelet Aggregation response to the following •Adenosine Diphosphate (ADP) •Collagen •Epinephrine •Ristocetin •Reflexed when appropriate •Arachidonic Acid Aggregation |
| |
| CPT: |
85576 (x4) Reflexed when appropriate 85576 |
| |
| Alternate Name: |
Aggregometer Test; Platelet Function Studies |
| |
| Methodology: |
Aggregometry |
| |
| Testing Schedule: |
Testing is performed by appointment only, please schedule in advance. |
| |
| Report Available: |
1-3 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
30 mL whole blood at room temperature. |
| |
| Container: |
8 Blue top (sodium citrate) tubes |
| |
| Collection: |
See special handling instructions for “Coagulation Studies”, listed under Specimen Collection, Preparation, and Handling Section |
| |
| Special Instructions and/or Comments: |
•For 14 days prior to testing, use of drugs that inhibit platelet aggregation are contraindicated (ie, acetylsalicylic acid, antihistamines, chlordiazepoxide, clofibrate, cocaine, corticosteroids, diazepam, dipyridamole, furosemide, gentamicin, ibuprofen, indomethacin, marijuana, phenothiazines, phenylbutazone, propranolol,pyrimidine, sulfinpyrazone, theophylline, tricyclic anti depressants). •Patient should be fasting prior to collecting specimen •Transport tubes at room temperature and deliver immediately to the testing department (testing must be completed within 4 hours of collection).DO NOT chill; platelets are activated at low temperatures. •DO NOT centrifuge or aliquot.Must remain as whole blood in original tube. Causes for rejection •Extended transport time to laboratory •Clotted specimens •Hemolyzed specimens •Blue top sodium citrate tubes insufficiently filled |
| |
| Reference Range: |
•ADP................................70% to 90% •Epinephrine ...................70% to 90% •Collagen ........................60% to 80% •Ristocetin........................81% to 97% •Arachadonic Acid ..........70% to 90% |
| |
| Clinical Utility: |
| Measures adhesion and aggregation of blood platelets. |
| |
Print |
| Platelet Antibody, Direct |
| |
| CPT: |
86022 |
| |
| Alternate Name: |
Cell Bound Platelet Antibody |
| |
| Methodology: |
Enzyme-Linked Immunosorbent Assay (ELISA) |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
10-12 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
Volume5 mL whole blood |
| |
| Container: |
Yellow top (ACD Solution A) tube |
| |
| Special Instructions and/or Comments: |
•Collect Monday-Friday ONLY before 1400, no holidays.Specimens must arrive in the laboratory no later than 1600. •Store as whole blood in original tube at room temperature. •DO NOT centrifuge, aliquot, refrigerate or freeze. •Patient must have a platelet count above 500 mm3. |
| |
| Reference Range: |
| • If positive, add to negative glycoprotein specificity will be identified |
| |
| Clinical Utility: |
| Useful for diagnosis of Idiopathic (autoimmune) thrombocytopenia purpura.Diagnosis ofimmunethrombocytopenia associated with SLE or other disorders associated with autoimmune phenomena. |
| |
Print |
| Platelet Antibody, Indirect |
| |
| CPT: |
86022 |
| |
| Methodology: |
Enzyme-Linked Immunosorbent Assa (ELISA) |
| |
| Testing Schedule: |
Routine, 3 times per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL serum |
| |
| Container: |
Red top tube, no serum separator |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
Negative NOTE When the patient’s serum is positive, the specific platelet glycoprotein will be identified as well as the probable specificity. The platelet glycoproteins reported areIIb/IIIa, Ia/IIa, GPIb/IX. In addition, this assayscreens for HLA Class I antibodies, but specificity is notdetermined. |
| |
| Clinical Utility: |
| Useful for, Evaluating cases of immune platelet refractoriness, post-transfusion purpura, or neonatal alloimmune thrombocytopenic purpura. |
| |
Print |
| Platelet Count, Blue Top (Sodium Citrate) Tube |
| |
| Includes: |
Evaluation on peripheral smear |
| |
| CPT: |
85049 |
| |
| Methodology: |
Automated Analyzer |
| |
| Testing Schedule: |
Routine STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1.5 mL whole blood |
| |
| Container: |
Full blue top (sodium citrate) tube |
| |
| Special Instructions and/or Comments: |
| DO NOT spin. |
| |
| Reference Range: |
< 4days:......................100-350x109 >4 days.......................100-400x109/L >1 month:...................150-400x109/L |
| |
| Critical Values: |
<50 x 109/L >750 x 109/L |
| |
| Clinical Utility: |
| Used to determine the platelet count when clumped platelets were present with the lavender top(EDTA) tube. |
| |
Print |
| Platelet Count, Whole Blood |
| |
| Includes: |
Automated Platelet Count Evaluation of peripheral smear if deemed necessary by set laboratory criteria |
| |
| CPT: |
85049 |
| |
| Alternate Name: |
Thrombocyte Count |
| |
| Methodology: |
Automated Analyzer |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1.5 mL whole blood OR 300- 500 µL in BD Microtainer™ tube |
| |
| Container: |
Lavender top (EDTA) tube OR lavender top BD Microtainer™ tube for capillary collection. |
| |
| Special Instructions and/or Comments: |
| If clumped platelets are detected and an exact Platelet Count is desired, it is recommended that a follow up specimen be submitted for a Platelet Count, Blue Top (Sodium Citrate) Tube (PTLVR). |
| |
| Reference Range: |
<4 days ................................100-350x109/L >=4 days...............................100-400x109/L >=1 month ...........................150-400x109/L |
| |
| Critical Values: |
<50 x 109/L >750 x 109/L |
| |
| Clinical Utility: |
| Used to evaluate and monitor bleeding and other hematological and coagulation disorders, DIC, leukemias and chemotherapeutic management of malignant disease. |
| |
Print |
| Platelet Function Studies |
| |
| See Platelet Aggregation |
Print |
| Pleural Fluid Culture |
| |
| See Culture, Fluid, Aerobic |
Print |
| Pleural Fluid Cytology |
| |
| See Cytopathology, Fluid |
Print |
| Pleural Fluid Profile |
| |
| Includes: |
Cell Count Glucose, Fluid Lactate Dehydrogenase, Fluid Protein, Total, Fluid |
| |
| CPT: |
89050, 89051, 82945, 83615, 84157, 88107 |
| |
| Alternate Name: |
Fluid Analysis, Pleural Fluid |
| |
| Methodology: |
See individual test listings. |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL body fluid in each tube |
| |
| Container: |
Red top tube, no serum separator AND lavender top (EDTA) tube |
| |
| Reference Range: |
| See individual test listings. |
| |
| Clinical Utility: |
| Used to evaluate the cause of pleural effusions. |
| |
Print |
| PM-1 Antibody |
| |
| See PM/Scl Autoantibody |
Print |
| PM/Scl AutoantibodyA |
| |
| CPT: |
86331 |
| |
| Alternate Name: |
Anti-PM-1 Antibody; PM-1 Antibody; Polymositis- Scleroderma Antibody |
| |
| Methodology: |
Immunodiffusion |
| |
| Testing Schedule: |
Routine, 1 time per week |
| |
| Report Available: |
7-10 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
Print |
| Pneumococcal Antibody Profile, Vaccine Response |
| |
| Includes: |
IgG Antibodies to the following Streptocococcus pneumoniae serotypes 1, 2, 3, 4 , 5, 8, 9N, 12F, 14, 17F, 19F, 20, 22F, 23F, 6B, 10A, 11A, 7F, 15B, 18C, 19A, 9V, and 33F. |
| |
| CPT: |
86317 (x23) |
| |
| Methodology: |
Microsphere Photometry |
| |
| Testing Schedule: |
Routine, Monday-Friday ONLY |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
•Centrifuge, transfer to plastic aliquot tube and freeze.Once frozen, transport specimen submerged in dry ice. •Please note if specimens are pre- or post-vaccination. |
| |
| Reference Range: |
| See report |
| |
| Clinical Utility: |
Useful for • Assessing the response to active immunization with nonconjugated 23-valent vaccines. • Determining the ability of an individual to respond to polysacchride antigen. |
| |
Print |
| Pneumococcal IgG Antibody 23 Serotypes |
| |
| See Pneumococcal Antibody Profile, Vaccine Response |
Print |
| Pneumocystis carinii, Direct Fluorescence |
| |
| CPT: |
87281 |
| |
| Alternate Name: |
Pneumocystis carinii Stain |
| |
| Methodology: |
Direct Immunofluorescence |
| |
| Report Available: |
1 day |
| |
| Special Instructions and/or Comments: |
| Transport to the laboratory within 1 hour of collection or refrigerate for up to 24 hours. |
| |
| Reference Range: |
| No Pneumocystis seen |
| |
| Clinical Utility: |
| Pneumocystis carinii can infect the lungs and cause a lethal pneumonia in immunocompromised patients and is the leading opportunistic infection associated with AIDS. |
| |
Print |
| Pneumocystis carinii Stain |
| |
| See Pneumocystis carinii, Direct Fluorescence |
| See Histopathology, Pneumocystis carinii Preparation (if tissue specimen) |
Print |
| Poliovirus Antibody Profile |
| |
| Includes: |
Poliovirus 1, 2 and 3 Antibodies |
| |
| CPT: |
86658 for each (x3) |
| |
| Methodology: |
Complement Fixation |
| |
| Testing Schedule: |
Routine, 3 times per week |
| |
| Report Available: |
7-10 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
| <1:8....Antibody not detected. |
| |
| Clinical Utility: |
| Because CF antibody levels usually persist for only a few months, any measurable titer may indicate recent exposure. Single titers 132 provide strong evidence for recent exposure. A four-fold or greater increase in titer between acute and convalescent specimens confirms recent exposure orinfection. |
| |
Print |
| Poliovirus Antibody, Vaccine Response |
| |
| Includes: |
Poliovirus 1, 2 and 3 Antibodies |
| |
| CPT: |
86382 (x3) |
| |
| Alternate Name: |
• Poliovirus Ab • Vaccine response • Polio Ab |
| |
| Methodology: |
Viral Antibody Neutralization |
| |
| Testing Schedule: |
Routine, 1 time per week |
| |
| Report Available: |
7-10 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
Refrigerate Please note if specimens are pre- or post-vaccination. |
| |
| Reference Range: |
| See report. |
| |
| Clinical Utility: |
| The presence of neutralizing serum antibodies (titers 1:8 or greater) against polioviruses implies lifelong immunity. The serum neutralization test is type specific; antibodies detected against one type does not indicate immunity against other types. However, some persons without detectable titers (< 1:8) may also be immune. This has been demonstrated by elicitation of a secondary-type serum antibody response upon rechallenge with live polio vaccine. |
| |
Print |
| Poliovirus Antibody Viral Neutralization |
| |
| See Poliovirus Antibody, Vaccine Response |
Print |
| Polymositis-Scleroderma Antibody |
| |
| See PM/Scl AutoantibodyPork Tapeworm |
| See Parasite Identification |
Print |
| Porphobilinogen, Random Urine |
| |
| CPT: |
84110 |
| |
| Methodology: |
Liquid Chromatograph /Tandem Mass Spectrometry (LC-MS/MS) 3 table Isotope Dilution Analysis |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
20 mL random urine |
| |
| Container: |
Plastic 60 mL amber urine bottle or sterile plastic urine cup. |
| |
| Special Instructions and/or Comments: |
•Send specimen frozen in a plastic urine container. Once frozen, transport specimen submerged in dry ice. •Protect from light by wrapping the entire bottle with aluminum foil. |
| |
| Reference Range: |
| < 1.3 mcmol/L |
| |
| Clinical Utility: |
| Useful for, first-line test for establishing a tentative diagnosis for acute neuropathic porphyria including acute intermittent porphyria (AIP), hereditary coproporphyria (HCP), and variegate porphyria (VP). |
| |
Print |
| Porphyrins, Quantitative, 24-Hour Urine |
| |
| Includes: |
• Volume Measurement • Collection Period • Uroporphyrin • Heptacarboxylporphyrin • Hexacarboxylprophyrin • Pentacarboxylporphyrin • Coproporphyrin • Porphobilinogen |
| |
| CPT: |
81050, 84110, 84120 |
| |
| Methodology: |
High Performance Liquid Chromatography (HPLC) with Fluorometric Detection and Liquid Chromatography-tandem mass spectrometry (LC-MS/MS) for porphobilinogen |
| |
| Testing Schedule: |
Routine, Monday-Friday ONLY |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
25-50 mL aliquot of a well mixed 24-Hour urine collection |
| |
| Container: |
24-Hour plastic urine container. Add 5 g of Na2CO3 at beginning of collection. |
| |
| Collection: |
•Instruct the patient to void at the beginning of the collection period and discard the specimen. •Collect all urine, including the final specimen voided at the end of collection period. •Refrigerate during collection. •Container must be labeled with the patient’s name. |
| |
| Special Instructions and/or Comments: |
•Instruct patient not to void directly into container. •Protect from light by wrapping the entire container with aluminum foil. •Transport to the laboratory promptly. •Requisition must state date and time collection began and date and time collection was completed. |
| |
| Reference Range: |
•Uroporphyrin................................... < 30 nmol/24 hrs •Heptacarboxylporphyrin.................. < 9 nmol/24 hours •Hexacarboxylporphyrin................... < 8 nmol/24 hours •Pentacarboxylporphyrin .................. < 10 nmol/24 hours •Coproporphyrin •Males.................. < 230 nmol/24 hours •Females.............. < 168 nmol/24 hours •Porphobilinogen.............. < 2.2 mcmol/24 hours |
| |
| Clinical Utility: |
| The measurement of PBG is important in the diagnosis of acute, neurologic porphyrias including acute intermittent porphyria (AIP), hereditary coproporphyria (HCP), and variegate porphyria (VP). Urinary porphyrin determination is helpful in the diagnosis of these disorders, as well as other porphyrias including congenital erythropoietic porphyria (CEP) and porphyria cutanea tarda (PCT). |
| |
Print |
| Postbronchoscopy Sputum |
| |
| See Cytopathology, Sputum Series |
Print |
| Postmortem Examination |
| |
| See Histopathology, Autopsy |
Print |
| Potassium, Body Fluid |
| |
| CPT: |
84999 |
| |
| Alternate Name: |
Body Fluid K; Body Fluid Potassium; K, Body Fluid |
| |
| Methodology: |
Potentiometry |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL body fluid |
| |
| Container: |
Red top tube, no serum separator |
| |
| Special Instructions and/or Comments: |
| Requisition must state site of specimen. |
| |
| Reference Range: |
| Not established, must be interpreted with clinical findings. |
| |
Print |
| Potassium, Serum |
| |
| CPT: |
84132 |
| |
| Alternate Name: |
K+; K, Blood; Serum Potassium |
| |
| Methodology: |
Potentiometry |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
•Transport to the laboratory immediately. •If testing cannot be performed within 4 hours of collection, centrifuge, transfer to plastic aliquot tube and refrigerate. |
| |
| Reference Range: |
•<11 days:................3.7-5.9 mEq/L • >11 days................3.5-5.2 mEq/L |
| |
| Critical Values: |
•<3.0 mEq/L •>6.0 mEq/L |
| |
| Clinical Utility: |
| Used to evaluate electrolyte and acid/base balance,cardiac arrhythmias, diuretic therapy and renal conditions. |
| |
Print |
| Potassium Hydroxide Preparation |
| |
| See KOH/Calcofluor Prep |
Print |
| Potassium, Urine 24-Hour |
| |
| Includes: |
Volume Measurement Collection Period Creatinine, Urine Potassium, Urine |
| |
| CPT: |
84133, 81050 |
| |
| Alternate Name: |
K+, Urine; Urine K+ |
| |
| Methodology: |
Potentiometry and Two-point Rate |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
Entire 24-Hour urine collection |
| |
| Container: |
Entire 24-Hour plastic urine container, no preservative |
| |
| Special Instructions and/or Comments: |
| Transport to the laboratory promptly. |
| |
| Clinical Utility: |
| Used to evaluate electrolyte and acid base balance and hypokalemia. |
| |
Print |
| PR3 Autoantibody |
| |
| See Neutrophil Cytoplasmic Autoantibody Profile |
Print |
| Prealbumin |
| |
| CPT: |
84134 |
| |
| Methodology: |
Rate Nephelometry |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1-3 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Reference Range: |
| 21-41 mg/dL |
| |
| Clinical Utility: |
| Assess protein nutritional status; evaluate total parenteral nutrition |
| |
Print |
| Potassium, Urine Random |
| |
| CPT: |
84133 |
| |
| Alternate Name: |
K+, Urine; Urine K+ |
| |
| Methodology: |
Potentiometry |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL random urine |
| |
| Container: |
Plastic urine container |
| |
| Collection: |
Random |
| |
| Special Instructions and/or Comments: |
| Transport to the laboratory promptly. |
| |
| Reference Range: |
| 20-125 mEq/L |
| |
| Clinical Utility: |
| Used to evaluate electrolyte and acid base balance and hypokalemia. |
| |
Print |
| PR3 Autoantibody |
| |
| See Neutrophil Cytoplasmic Autoantibody Profile |
Print |
| Pregnancy Test |
| |
| See Beta Human Chorionic Gonadotropin, Serum See Beta Human Chorionic Gonadotropin, Urine |
Print |
| Prekallikrein |
| |
| CPT: |
85292 |
| |
| Alternate Name: |
Fletcher Factor |
| |
| Methodology: |
Clot Based Assay |
| |
| Testing Schedule: |
Routine, 1 time per week |
| |
| Report Available: |
7-10 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL plasma, split equally into 2 plastic aliquot tubes and FROZEN immediately |
| |
| Container: |
2 Blue top (sodium citrate) tubes |
| |
| Collection: |
See special handling instructions for “Coagulation Studies”, listed under Specimen Collection, Preparation, and Handling Section |
| |
| Special Instructions and/or Comments: |
•Testing is contraindicated for patients on Heparin or Coumadin® therapy. •Immediately centrifuge at 1500-1700 X G for 10 minutes.Avoiding the buffy coat, carefully remove the plasma from the cells using a plastic pipette.Aliquot the plasma into the required number of plastic aliquot tubes and label with “citrated plasma” labels. •Freeze the aliquoted specimens at –40° to –60°C.Once frozen, transport the specimens submerged in dry ice. Causes for rejection •Extended transport time to laboratory •Clotted specimens •Hemolyzed specimens •Blue top sodium citrate tubes insufficiently filled •Aliquots not received frozen on dry ice •Frozen aliquots not clearly identified as “citrated plasma” |
| |
| Reference Range: |
| 65-135% |
| |
| Clinical Utility: |
| Useful for explaining a prolonged PTTwhen all other coagulation factors are present in normal percentages. |
| |
Print |
| Prenatal Package 1 (No Urinalysis) |
| |
| See Obstetric Panel |
Print |
| Prenatal Package 2 (Includes Urinalysis) |
| |
| See Obstetric Profile with Urinalysis |
Print |
| Prenatal Screen |
| |
| See Obstetric Profile, Repeat Blood Bank Only |
Print |
| Prenatal Testing, Repeat Blood Bank Only |
| |
| See Obstetric Profile, Repeat Blood Bank Only |
Print |
| Primidone |
| |
| Includes: |
•Primidone •Phenobarbital metabolite |
| |
| CPT: |
80188, 80184 |
| |
| Alternate Name: |
Mysoline® |
| |
| Methodology: |
Immunoassay (IA) |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Reference Range: |
Therapeutic •Primidone 5.0-12.0µg/mL •Phenobarbital 15-40µg/mL |
| |
| Clinical Utility: |
| Useful for monitoring therapy and assessing toxicity. |
| |
Print |
| Procainamide |
| |
| Includes: |
• Procainamide • N-acetylprocainamide (NAPA) |
| |
| CPT: |
80192 |
| |
| Alternate Name: |
• Pronestyl® • NAPA • Acetylprocainamide |
| |
| Methodology: |
Immunoassay (IA) |
| |
| Testing Schedule: |
Routine |
| |
| Report Available: |
2-3 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1.0 mL serum (0.4mL minimum) |
| |
| Container: |
Red top tube, no serum separator |
| |
| Reference Range: |
Therapeutic •Procainamide......................................4-8 µg/mL •Sum of procainamide + NAPA..........<30 µg/mL |
| |
| Clinical Utility: |
| Useful for monitoring therapy and assessing toxicity. |
| |
Print |
| Progesterone, 17-Alpha-Hydroxy |
| |
| See 17-Hydroxyprogesterone |
Print |
| Progesterone, Serum |
| |
| CPT: |
84144 |
| |
| Methodology: |
Direct Chemiluminescence |
| |
| Testing Schedule: |
Routine, STAT testing available 0600-2100 |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
•Testing must be performed within 8 hours of collection. •If delay in transport centrifuge, transfer to plastic aliquot tube and refrigerate tube in the upright position.Specimen should remain capped until time of testing. |
| |
| Reference Range: |
Normal Females • Follicular Phase........... 0.15-1.40 ng/mL • Luteal Phase.................3.34-25.56 ng/mL • Mid-Luteal Phase.........4.44-28.03 ng/mL Pregnant Female • First Trimester.............11.22-90.00 ng/mL • Second Trimester.........25.55-89.40 ng/mL • Third Trimester...........48.40-422.50 ng/mL Postmenopausal:..............< 0.74 ng/mL Males:............................... 0.28-1.22 ng/mL |
| |
| Clinical Utility: |
| Used in the evaluation of infertility, ovulation and to monitor the success of induced ovulation. |
| |
Print |
| Progressive Systemic Sclerosis Antibody |
| |
| See Scl-70 Autoantibody |
Print |
| Proinsulin |
| |
| CPT: |
84206 |
| |
| Methodology: |
Immunochemiluminescent Assay |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
7-10 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1.5 mL EDTA plasma |
| |
| Container: |
Prechilled lavender top (EDTA) tube |
| |
| Collection: |
Overnight fast required. |
| |
| Special Instructions and/or Comments: |
•Transport to the laboratory immediately. •Must be processed and frozen immediately. •Centrifuge, transfer to plastic aliquot tube and freeze.Once frozen, transport specimen submerged in dry ice. |
| |
| Reference Range: |
| 3-20 pmol/L |
| |
| Clinical Utility: |
| Diagnosis of insulinoma. |
| |
Print |
| Prolactin, Serum |
| |
| CPT: |
84146 |
| |
| Methodology: |
Direct Chemiluminescence |
| |
| Testing Schedule: |
Routine, STAT testing available 0600-2100 |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube, |
| |
| Special Instructions and/or Comments: |
•Testing must be performed within 8 hours of collection. •If delay in transport, centrifuge, transfer to plastic aliquot tube and refrigerate tube in the upright position. Specimen should remain capped until time of testing. |
| |
| Reference Range: |
Females • Non-pregnant:.................2.8-29.2 ng/mL • Pregnant:.........................9.7-208.5 ng/mL • Postmenopausal..............1.8-20.3 ng/mL Males2.1-17.7 ng/mL |
| |
| Clinical Utility: |
| Used in the evaluation of infertility, amenorrhea,galactorrhea, pituitary tumors and in the monitoring of prolactinoma treatment. |
| |
Print |
| Prolan A |
| |
| See Follicle Stimulating Hormone,Serum |
Print |
| Prolixin® |
| |
| See Fluphenazine |
Print |
| Pronestyl® |
| |
| See ProcainamideProperdin Factor B |
| See Complement, C3 Proactivator |
Print |
| Propoxyphene, Qualitative, Urine |
| |
| Includes: |
Identification of propoxyphene and/or metabolite norpropoxyphene |
| |
| CPT: |
80101 |
| |
| Alternate Name: |
Darvocet-N®; Darvon® |
| |
| Methodology: |
Immunoassay (IA) |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL urine |
| |
| Container: |
Plastic urine container |
| |
| Special Instructions and/or Comments: |
| If for forensic or legal purposes, submit specimen with a completed Drug Testing Request and Chain-of-Custody (HNL-53) Form or Blood Alcohol Toxicology Request/Chain-of-Custody (LAB-53) Form in plastic evidence bag. |
| |
| Reference Range: |
None detected NOTE Confirmation by GC/MS (gas chromatography/mass spectrometry) available upon request.Contact Customer Care 610-402-8170 for instructions. |
| |
| Clinical Utility: |
| A qualitative screen useful for detection of drug abuse/use of propoxyphene.Confirmation of a positive screening result by GC/MS is strongly recommended. |
| |
Print |
| Propoxyphene, Quantitative, Blood |
| |
| Includes: |
Identification and quantitation of propoxyphene and norpropoxypheneby |
| |
| CPT: |
82542 |
| |
| Methodology: |
Gas Chromatography-Mass Spectroscopy |
| |
| Testing Schedule: |
Once/week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL whole blood |
| |
| Container: |
1 gray top or lavendar top |
| |
| Reference Range: |
| Therapeutic range for Propxyphene + Norpropoxyphene is 1.0-3.7 ug/mL |
| |
| Clinical Utility: |
| To determine blood level of propoxyphene to determine toxicity or overdose. |
| |
Print |
| Propranolol |
| |
| CPT: |
80299 |
| |
| Alternate Name: |
Inderal® |
| |
| Methodology: |
High performance Liquid Chromatography (HPLC)) |
| |
| Testing Schedule: |
Routine, 1 time per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Red top tube, no serum separator |
| |
| Collection: |
Optimum time to collect trough specumens is just prior to the next dose. Patient should refrain from taking propafenone (Rythmol) one week prior to specimen collection |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
| Therapeutic Concentration.....................30-100 ng/mL |
| |
| Clinical Utility: |
| Useful for monitoring compliance. |
| |
Print |
| Propoxyphene, Urine, GCMS |
| |
| Includes: |
Identification and quantitation of propoxyphene and norpropoxypheneby GCMS |
| |
| CPT: |
82542 |
| |
| Methodology: |
Gas Chromatography/Mass Spectroscopy (GC/MS) |
| |
| Testing Schedule: |
3 times/week |
| |
| Report Available: |
2-4 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL random urine |
| |
| Container: |
Plastic urine container |
| |
| Special Instructions and/or Comments: |
| If for forensic or legal purposes, submit specimen with a completed Drug TestingRequest and Chain-of-Custody (HNL-53) Formor Blood Alcohol Toxicology Request/Chain-of-Custody (LAB-32) Form. |
| |
| Reference Range: |
| None present |
| |
| Clinical Utility: |
| Useful for the detection and positive identification of propoxyphene and norpropoxyphene in urine. |
| |
Print |
| Prostate Specific Antigen, Free and Total |
| |
| Includes: |
Prostate Specific Antigen, Total Prostate Specific Antigen, Free Prostate Specific Antigen, % Free (calculation) |
| |
| CPT: |
84153, 84154 |
| |
| Alternate Name: |
Free PSA |
| |
| Methodology: |
Chemiluminescent Microparticle Immunoassay (CMIA) |
| |
| Testing Schedule: |
Routine, 3 times per week |
| |
| Report Available: |
1-3 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
• Must be processed and frozen within 24 hours of collection. • Centrifuge, transfer to plastic aliquot tube, transport specimen refrigerated. |
| |
| Reference Range: |
Prostate Specific Antigen, Total............... <4.00 ng/mL Prostate Specific Antigen, Free.................N/A Prostate Specific Antigen, % Free See “Interpretation Chart” below % Free PSA Interpretation* | % Free PSA Value | Probability of Prostate Cancer | | <10% | 67.9% | | 10-15% | 50.0% | | 15-20% | 32.1% | | 20-26% | 18.3% | | >26% | 9.6% |
*Please note that the clinical utility of % Free PSA has not been determined for values <4.00 or >10.00 ng/mL. |
| |
| Clinical Utility: |
| Testing is best utilized as a follow up on patients previously determined to have Total PSA values in the range of 4.00-10.00 ng/mL. In this range, the measurement of Free PSA and the calculation of a % Free PSA value are helpful in the discrimination of prostate cancer from benign disease. |
| |
Print |
| Prostate Specific Antigen, Total |
| |
| CPT: |
84153 |
| |
| Alternate Name: |
PSA; PSAG; PSA Screen |
| |
| Methodology: |
Chemiluminescent Microparticle Immunoassay (CMIA) |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1-3 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
•If specimen cannot be tested within 72 hours, centrifuge, transfer to plastic aliquot tube and freeze.Once frozen, transport specimen submerged in dry ice. •It is recommended to obtain specimens for PSA testing prior to procedures involving manipulation of the prostate.In most instances specimens obtained from patients immediately following digital rectal examination (DRE) show no clinically significant elevations in PSA levels.However, prostatic massage, ultrasonography and needle biopsy may cause clinically significant elevations. PSA levels may also be increased following ejaculation. •The concentration of PSA in a given specimen, determined with assays from different manufacturers, can vary due to differences in assay methods, calibration, and reagent specificity. •When monitoring a patient sequentially for cancer management, the same assay should be consistently utilized. •Avoid palpation of the prostate for 2 weeks prior to testing. Rectal examination within 48 hours of specimen collection may cause elevation of results. |
| |
| Reference Range: |
| <4.00 ng/mL |
| |
| Clinical Utility: |
Determination of Total PSA levels are useful asAn aid in the detection of prostate cancer when used in conjunction with digital rectal examination (DRE) in men 50 years or older. An adjunctive test to aid in management of prostate cancer patients. |
| |
Print |
| Prostate Specific Antigen, Total, Screen |
| |
| CPT: |
84153, G0103 |
| |
| Alternate Name: |
PSA; PSAG; PSA Screen |
| |
| Methodology: |
Chemiluminescent Microparticle Immunoassay (CMIA) |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1-3 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
•If specimen cannot be tested within 72 hours, centrifuge, transfer to plastic aliquot tube and freeze.Once frozen, transport specimen submerged in dry ice. •It is recommended to obtain specimens for PSA testing prior to procedures involving manipulation of the prostate.In most instances specimens obtained from patients immediately following digital rectal examination (DRE) show no clinically significant elevations in PSA levels.However, prostatic massage, ultrasonography and needle biopsy may cause clinically significant elevations. PSA levels may also be increased following ejaculation. •The concentration of PSA in a given specimen, determined with assays from different manufacturers, can vary due to differences in assay methods, calibration, and reagent specificity. •When monitoring a patient sequentially for cancer management, the same assay should be consistently utilized. •Avoid palpation of the prostate for 2 weeks prior to testing. Rectal examination within 48 hours of specimen collection may cause elevation of results. |
| |
| Reference Range: |
| <4.00 ng/mL |
| |
| Clinical Utility: |
| Determination of Total PSA levels are useful asAn aid in the detection of prostate cancer when used in conjunction with digital rectal examination (DRE) in men 50 years or older. An adjunctive test to aid in management of prostate cancer patients. |
| |
Print |
| Prostate Specific Antigen, Total, with Reflex PSA, Free |
| |
| Includes: |
•Prostate Specific Antigen, Total •Reflexed on Total PSA values in the range of 4.00-10.00 ng/mL •Prostate Specific Antigen, Free •Prostate Specific Antigen, % Free (calculation) |
| |
| CPT: |
84153 Reflexed when appropriate 84154 |
| |
| Methodology: |
Chemiluminescent Microparticle Immunoassay (CMIA) |
| |
| Testing Schedule: |
Routine, 3 times per week |
| |
| Report Available: |
1-3 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
•Must be processed and frozen within 24 hours of collection. •Centrifuge, transfer to plastic aliquot tube and freeze. Once frozen, transport specimen submerged in dry ice. |
| |
| Reference Range: |
Prostate Specific Antigen, Total................... <4.00 ng/mL Prostate Specific Antigen, Free.....................N/A Prostate Specific Antigen, % Free See “Interpretation Chart” below % Free PSA Interpretation* | % Free PSA Value | Probability of Prostate Cancer | | <10% | 67.9% | | 10-15% | 50.0% | | 15-20% | 32.1% | | 20-26% | 18.3% | | >26% | 9.6% |
*Please note that the clinical utility of % Free PSA has not been determined for Total PSA values <4.00 or >10.00 ng/mL. |
| |
| Clinical Utility: |
In patients not previously diagnosed with prostatic cancer, Total PSA screening values in the range of 4.00-10.00 ng/mL warrant further testing as an aid in discriminating between prostate cancer and benign disease. Reflex testing with a Free PSA assay and the calculation of a % Free PSA value may improve the discrimination in men with intermediate levels of Total PSA and non-suspicious digital rectal examination (DRE). |
| |
Print |
| Prostatic Acid Phosphatase |
| |
| See Acid Phosphatase, Prostatic |
Print |
| Prostatic Fluid Culture |
| |
| See Culture, Genital |
| See Culture, Fluid, Aerobic |
Print |
| Protein Bound Glucose |
| |
| See FructosamineProtein C |
| See Protein C, Functional |
Print |
| Protein C, Functional |
| |
| CPT: |
85303 |
| |
| Alternate Name: |
Protein C |
| |
| Methodology: |
Clot Based Assay |
| |
| Testing Schedule: |
Routine, 1 time per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL prepared “platelet poor plasma” split equally into 2 plastic aliquot tubes and FROZEN immediately. |
| |
| Container: |
2 Blue top (sodium citrate) tubes |
| |
| Collection: |
See special handling instructions for “Coagulation Studies”, listed under Specimen Collection, Preparation, and Handling |
| |
| Special Instructions and/or Comments: |
•Testing is contraindicated for patients on Heparin or Coumadin therapy. •Preparation and submission of “platelet poor plasma” is critical for accurate test performance and interpretation.See collection note above. Causes for rejection •Extended transport time to laboratory •Clotted specimens •Hemolyzed specimens •Blue top sodium citrate tubes insufficiently filled •Aliquots not received frozen on dry ice •Frozen aliquots not clearly identified as “platelet poor plasma” |
| |
| Reference Range: |
| 77% to 145% |
| |
| Clinical Utility: |
| Protein C deficiency can lead to thrombotic complications. Acquired Protein C deficiency is noted in coumadin therapy, DIC, acute thromboembolic disease, severe liver disease, hemolytic uremic syndrome and in TTP. |
| |
Print |
| Protein, Cerebrospinal Fluid |
| |
| CPT: |
84157 |
| |
| Alternate Name: |
Cerebrospinal Fluid Protein; CSF Protein; Protein, CSF |
| |
| Methodology: |
Endpoint |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
0.5 mL cerebrospinal fluid |
| |
| Container: |
Sterile conical tube |
| |
| Special Instructions and/or Comments: |
• Testing should be performed on tube #1. • Tubes must be numbered indicating the sequence of collection. |
| |
| Reference Range: |
• <1 month.....................30-170 mg/dL • >1 month:...................30-100 mg/dL • >7 months..................12-60 mg/dL |
| |
| Critical Values: |
| >75 mg/dL |
| |
| Clinical Utility: |
| Used in the evaluation of infection, inflammation, trauma, malignancy and other disorders of the central nervous system. |
| |
Print |
| Protein/Creatinine Ratio, Random Urine |
| |
| Includes: |
Creatinine, Urine Protein, Total, Urine |
| |
| CPT: |
82570, 84156 |
| |
| Methodology: |
See individual test listings |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL random urine |
| |
| Container: |
Plastic urine container |
| |
| Reference Range: |
• Protein, Total, Random Urine..............<12 mg/dL • Creatinine, Random Urine..................50-200 mg/dL • Ratio<0.15 |
| |
| Clinical Utility: |
| Used to evaluate proteinuria and renal disorders. |
| |
Print |
| Protein, CSF |
| |
| See Protein, Cerebrospinal Fluid |
Print |
| Protein Electrophoresis, Cerebrospinal Fluid |
| |
| CPT: |
84157, 84166 |
| |
| Alternate Name: |
•CSF Electrophoresis •Electrophoresis, Protein, CSF |
| |
| Methodology: |
Agarose Gel Electrophoresis, Spectrophotometry |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
3 mL cerebrospinal fluid |
| |
| Container: |
Sterile conical tube |
| |
| Reference Range: |
•Protein CSF...............................15 to 45 mg/dL •Prealbumin CSF..........................2 to 7 % •Albumin CSF............................57 to 76 % •Alpha1 CSF................................1 to 7 % •Alpha2 CSF................................3 to 13 % •Beta CSF....................................7 to 18 % •Gamm CSF.................................3 to 13 % Report includes an interpretation |
| |
| Clinical Utility: |
| Useful in the evaluation of meningitis,tuberculosis, brain abscess, meningovascular syphilis, CVA, neoplastic disease, multiple sclerosis, and other degenerative processes causing neurological disease. |
| |
Print |
| Protein Electrophoresis, Serum |
| |
| Includes: |
•Protein, Total, Serum •Quantitations of Albumin, Alpha-1, Alpha-2, Beta and Gamma Fractions •Scan with Pathologist’s Interpretive Report •Serum IEP/IFE Profile is performed if abnormal results are observed on the SPEPscreen |
| |
| CPT: |
84155 , 84165 Reflexed when appropriate 82784 (x3), 86334 |
| |
| Alternate Name: |
Electrophoresis, Serum; Serum Protein Electrophoresis; SPE; SPEP |
| |
| Methodology: |
Agarose Gel Electrophoresis |
| |
| Testing Schedule: |
Routine, 3-5 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
•Testing is contraindicated on hemolyzed or grossly lipemic specimens. •Plasma specimens are unacceptable. |
| |
| Reference Range: |
•Total protein.....................6.0-8.0 g/dL •Albumin...........................3.2-4.2 g/dL •Alpha1 region..................0.1-0.4 g/dL •Alpha2 region..................0.7-1.1 g/dL •Beta region......................0.8-1.3 g/dL •Gamma region.................0.7-1.7 g/dL |
| |
| Clinical Utility: |
| Useful for chronic active hepatitis; useful in the evaluation of myeloma, macroglobulinemia of Waldenstrom, collagen diseases, and monoclonal gammopathies; evaluate inflammatory states; evaluate low back pain, arthritis, amyloidosis; evaluate lymphoma, leukemia, anemia. |
| |
Print |
| Protein Electrophoresis, Urine |
| |
| Includes: |
•Scan with Pathologist’s Interpretive Report •Urine IEP/IFE Profile is performed if abnormal results are observed on the UPEP screen |
| |
| CPT: |
84166 Reflexed when appropriate 86335 |
| |
| Alternate Name: |
Bence Jones Protein; BJP; Electrophoresis, Protein, Urine; Globulins, Urine; UPE; UPEP; Urine Electrophoresis; Urine Protein Electrophoresis |
| |
| Methodology: |
Agarose Electrophoresis Gel |
| |
| Testing Schedule: |
Routine, 3-5 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
20-40 mL random urine OR 20-40 mL aliquot of a well- mixed 24-Hour urine collection ContainerPlastic urine container OR 24-Hour plastic urine container, no preservative |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
| Negative no protein present; no suggestion of monoclonal free light chains (Bence Jones protein). |
| |
Print |
| Protein S |
| |
| See Protein S, Functional |
Print |
| Protein S, Functional |
| |
| CPT: |
85306 |
| |
| Alternate Name: |
Protein S |
| |
| Methodology: |
Clot Based Assay |
| |
| Testing Schedule: |
Routine, 1 time per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL prepared “platelet poor plasma” split equally into 2 plastic aliquot tubes and FROZEN immediately. |
| |
| Container: |
2 Blue top (sodium citrate) tubes |
| |
| Collection: |
See special handling instructions for “Coagulation Studies”, listed under Specimen Collection, Preparation, and Handling Section |
| |
| Special Instructions and/or Comments: |
•Testing is contraindicated for patients on Heparin or Coumadin therapy. •Preparation and submission of “platelet poor plasma” is critical for accurate test performance and interpretation.See collection note above. Causes for rejection •Extended transport time to laboratory •Clotted specimens •Hemolyzed specimens •Blue top sodium citrate tubes insufficiently filled •Aliquot not received frozen on dry ice •Frozen aliquots not clearly identified as “platelet poor plasma” |
| |
| Reference Range: |
| 70% to 125% |
| |
| Clinical Utility: |
| Hereditary protein S deficiency is associated with recurrent venous thromboembolic disease often presenting in adolescents or young adults. Protein Slevels are low in pregnancy and coumadin therapy. Acquired Protein S deficiency is documented in DIC, Type I and II diabetes mellitus, pregnancy, oralcontraceptive use, nephrotic syndrome, liver disease, and essential thrombocythemia. |
| |
Print |
| Protein, Total, Body Fluid |
| |
| CPT: |
84157 |
| |
| Alternate Name: |
Body Fluid Protein |
| |
| Methodology: |
Endpoint |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL body fluid |
| |
| Container: |
Red top tube, no serum separator |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
Not established, must correlate with clinical findings. NOTE Pleural fluid Transudate.............<3 g/dL Pleural fluid Exudate..................>3 g/dL |
| |
| Clinical Utility: |
| To aid in the evaluation of effusions and to help differentiate exudates from transudates. |
| |
Print |
| Protein, Total, Serum |
| |
| CPT: |
84155 |
| |
| Alternate Name: |
Total Protein, Blood |
| |
| Methodology: |
HNL Endpoint LPP Bichromatic endpoint |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Reference Range: |
• <1 month:..................4.6-7.0 g/dL •>1 month:...................4.5-6.5 g/dL •>6 months:.................5.4-7.5 g/dL •>2 years:....................5.3-8.0 g/dL •>16 years ...................6.3-8.2 g/dL |
| |
| Clinical Utility: |
Used to evaluate nutritional status, edema, hepatic, renal and other protein altering disorders. |
| |
Print |
| Protein, Total, Urine Random |
| |
| CPT: |
84156 |
| |
| Alternate Name: |
Quantitative Urine Protein; Total Protein, Urine; Urine Protein |
| |
| Methodology: |
Endpoint |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL random urine |
| |
| Container: |
Plastic urine container |
| |
| Collection: |
Random |
| |
| Reference Range: |
| <12 mg/dL |
| |
| Clinical Utility: |
| Used to evaluate proteinuria and monitor kidney function. |
| |
Print |
| Protein, Total, Urine24-Hour |
| |
| Includes: |
•Volume Measurement •Collection Period •Creatinine, Urine •Protein, Total, Urine |
| |
| CPT: |
81050, 84156 |
| |
| Alternate Name: |
Quantitative Urine Protein; Total Protein, Urine; Urine Protein |
| |
| Methodology: |
Endpoint |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
Entire 24-Hour urine collection |
| |
| Container: |
Entire 24-Hour plastic urine container, no preservative |
| |
| Collection: |
24-Hour urine collection See special instructions for “24-Hour Urine Collection”, listed under Specimen Collection, Preparation, and Handling Section |
| |
| Special Instructions and/or Comments: |
| Transport to the laboratory promptly. |
| |
| Reference Range: |
•Creatinine, 24-Hour Urine...........0.8-2.8 g/24 hours •Protein, 24-Hour Urine................0.04-0.23 g/24 hours |
| |
| Clinical Utility: |
| Used to evaluate proteinuria and monitor kidney function. |
| |
Print |
| Prothrombin (Factor II) Mutation |
| |
| See Prothrombin Gene Mutation, G20210A |
Print |
| Prothrombin Fragment 1 & 2 |
| |
| CPT: |
83520 |
| |
| Methodology: |
Enzyme-Linked Immunosorbent Assay (ELISA) |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL frozen plasma split equally into 2 plastic aliquot tubes and FROZEN immediately. |
| |
| Container: |
2 Blue top (sodium citrate) tubes |
| |
| Collection: |
See special handling instructions for “Coagulation Studies”, listed under Specimen Collection, Preparation, and Handling Section |
| |
| Special Instructions and/or Comments: |
•Testing is contraindicated for patients on Heparin or Coumadin therapy. •Immediately centrifuge at 1500-1700 X G for 10 minutes.Avoiding the buffy coat, carefully remove the plasma from the cells using a plastic aliquot pipette.Aliquot the plasma into the required number of plastic aliquot tubes and label with “cirated plasma” labels. •Freeze the aliquoted specimens at –40 to –60°C. Once frozen, transport the specimens submerged in dry ice. Causes for rejection •Extended transport time to laboratory •Clotted specimens •Hemolyzed specimens •Blue top sodium citrate tubes insufficiently filled •Aliquots not received frozen on dry ice •Frozen aliquots not clearly identified as “citrated plasma” |
| |
| Reference Range: |
| 87-325 pmol/L |
| |
| Clinical Utility: |
| This test assesses ongoing coagulation.Activation as may occur in thrombosis and DIC. |
| |
Print |
| Prothrombin Gene Mutation G20210A |
| |
| CPT: |
83890; 83896 (X2); 83898; 83912 |
| |
| Alternate Name: |
Factor II Mutation, DNA 20210; Prothrombin (Factor II) Mutation |
| |
| Methodology: |
Realtime PCR |
| |
| Testing Schedule: |
Routine 2x per week |
| |
| Report Available: |
1-3 working days |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL whole blood |
| |
| Container: |
1 Full Lavender top [EDTA] tube |
| |
| Special Instructions and/or Comments: |
•Store as whole blood in original tube. •Refrigerate at 2-8C only. •DO NOT centrifuge, aliquot or freeze. •Heparin specimen NOT acceptable |
| |
| Reference Range: |
| Not Detected. |
| |
| Clinical Utility: |
| Useful in detecting the Promthrombin G20210A Mutation for the evaluation of thrombotic risk. |
| |
Print |
| Prothrombin Time (PT) Profile |
| |
| Includes: |
• PT • PT mixing study reflexed when appropriate • Thrombin Time (TT) reflexed when appropriate • Reptilase Time (REPTL) reflexed when appropriate |
| |
| CPT: |
85610, Reflexed when appropriate, 85611, 85670, 85635 |
| |
| Alternate Name: |
PT mixing study; PT Profile |
| |
| Methodology: |
Mechanical Clot Detection |
| |
| Testing Schedule: |
Routine, Monday-Friday only |
| |
| Report Available: |
2-3 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL citrated plasma |
| |
| Container: |
4 full Blue top (sodium citrate) tubes |
| |
| Collection: |
See special handling instructions for “Coagulation Studies”, listed under Specimen Collection, Preparation, and Handling Section |
| |
| Special Instructions and/or Comments: |
• Testing is contraindicated for patients on heparin or Coumadin therapy. • Transport to the laboratory immediately. • If testing cannot be performed within 4 hours of collection, platelet pour plasma must be prepared prior to freezing. • Immediately centrifuge specimens at 1700 to 2000 g for 10 minutes • Remove the plasma and dispense into plastic aliquot tube. Spin aliquot for 10 minutes. • Remove the plasma and dispense into another plastic aliquot tube. Spin new aliquot for 10 minutes. Transfer plasma into 8 aliquot tubes and freeze. • Once frozen, specimens should be submerged in dry ice for transport.. |
| |
| Reference Range: |
| See report. |
| |
| Critical Values: |
PT.............>45.7 seconds* INR...........>4.9 * Value varies with reagent lot |
| |
| Clinical Utility: |
| A PT mixing study can differentiate between a coagulation factor deficiency or the presence of an inhibitor. |
| |
Print |
| Prothrombin Time with INR, Plasma |
| |
| Includes: |
• Prothrombin Time (PT) INR (international normalized ratio) • INR (International Normalized Ratio) |
| |
| CPT: |
85610 |
| |
| Alternate Name: |
Protime; PT |
| |
| Methodology: |
Mechanical Clot Detection |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL citrated plasma |
| |
| Container: |
Full blue top (sodium citrate) tube |
| |
| Collection: |
See special handling instructions for “Coagulation Studies”, listed under Specimen Collection, Preparation,and Handling Section |
| |
| Special Instructions and/or Comments: |
•Unopened (capped) tubes, uncentrifuged, or centrifuged, stored at 18-24.C (room temperature) and tested within 24 hours are acceptable. • If testing cannot be performed within 24 hours of collection, centrifuge the specimen at 3000 rpm for 15 minutes (5000 rpm for 5 minutes if using a hettich centrifuge), and transfer the plasma to a plastic aliquot tube and freeze. Once frozen, transport the specimen submerged in dry ice. •If plasma is not separated and frozen, testing cannot be added on to existing orders if it is more than 24 hours past the specimen draw time. If plasma is frozen, testing can be added. |
| |
| Reference Range: |
*Range/value varies with reagent lot. HNL.................12.0 - 14.2 seconds* LPP................. 11.0 - 13.7 seconds* |
| |
| Critical Values: |
* Range varies with reagent lot HNL PT.......> 49.1 seconds* INR.. ..> 4.9 LPP PT.......> 27.3 seconds* INR.... > 4.9 Clinical Condition INR Ambulatory Surgery < 1.5 Coumadinized Patients DVT, PE, MI, or A.Fib............2.0 - 3.0 Mechanical Heart Valve..........2.5 - 3.5 Cardiogenic Embolus..............2.5 - 3.5 |
| |
| Clinical Utility: |
| Used in the evaluation of the extrinsic coagulation system and in coagulation disorders / deficiencies. Also used in monitoring warfarin Coumadin® therapy. |
| |
Print |
| Protime |
| |
| See Prothrombin Time with INR, Plasma |
Print |
| Protoporphyrin, Zinc, Blood |
| |
| CPT: |
84202 |
| |
| Alternate Name: |
Zinc Protoporphyrin |
| |
| Methodology: |
Hematofluorometry |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL whole blood |
| |
| Container: |
Lavender top (EDTA) tube OR dark blue (EDTA or heparin) tube |
| |
| Special Instructions and/or Comments: |
•Store as whole blood in original tube. •DO NOT centrifuge, aliquot, refrigerate or freeze. •Protect from light by wrapping the entire tube with aluminum foil. |
| |
| Reference Range: |
| <35 .µg/dL |
| |
Print |
| Prozac® |
| |
| See Fluoxetine |
Print |
| PSA |
| |
| See Prostate Specific Antigen, Total OR Prostate Specific Antigen, Total, Screen |
Print |
| PSAG |
| |
| See Prostate Specific Antigen, Total OR Prostate Specific Antigen, Total, Screen |
Print |
| PSA Screen |
| |
| See Prostate Specific Antigen, Total OR Prostate Specific Antigen, Total, Screen |
Print |
| PSAT |
| |
| See Total Iron Binding Capacity Profile |
Print |
| Pseudocholinesterase, Serum |
| |
| CPT: |
82480 |
| |
| Alternate Name: |
Cholinesterase, Blood |
| |
| Methodology: |
Spectrophotography |
| |
| Testing Schedule: |
Routine, Daily |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Reference Range: |
Female:.............2673-6592 IU/L Male:.................3342-7586 IU/L |
| |
| Clinical Utility: |
Patients exposed to organophosphorus compounds exhibit decreased levels of cholinesterase. A 30-50% decrease is observed in acute hepatitis and chronic hepatitis of long duration. 50-70% decreases occur in advanced cirrhosis and carcinoma with metastases to the liver. Cholinesterase measurements are also used in the detection of patients with inherited abnormal variants of the enzyme. |
| |
Print |
| Pseudomembranous Colitis Toxin Assay |
| |
| See Clostridium difficile Toxin A/B Assay |
Print |
| PT |
| |
| See Prothrombin Time with INR, Plasma |
Print |
| PTH Related Protein |
| |
| See Parathyroid Hormone Related Peptide |
Print |
| PTHRP |
| |
| See Parathyroid Hormone Related Peptide |
Print |
| PTT |
| |
| See Partial Thromboplastin Time, Activated, Plasma |
Print |
| Pulmonary Cytology Series |
| |
| See Cytopathology, Sputum Series |
Print |
| Purkinje Cell Antibody (PCA-1) |
| |
| See Yo Autoantibody |
Print |
| Pus Culture |
| |
| See Culture, Wound, Aerobic |
Print |
| Pyruvate |
| |
| CPT: |
84210 |
| |
| Alternate Name: |
Pyruvic Acid |
| |
| Methodology: |
Spectrophotometry |
| |
| Testing Schedule: |
Routine, 3 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL whole blood added to special prechilled collection tube |
| |
| Container: |
Prior to collecting specimen, contact our Referral Testing Department at 610-402-5864 for a special prechilled collection tube containing 2.5 mL 6% perchloric acid into which blood will be transferred. |
| |
| Collection: |
Collect enough blood directly into syringe to add exactly 1.0 mL of blood to the special prechilled collection tube. |
| |
| Special Instructions and/or Comments: |
•Once drawn, immediately transfer 1.0 mL of blood to the special collection tube. •Shake vigorously to mix. •Transport to the laboratory refrigerated in the special collection tube. •DO NOT centrifuge, aliquot or freeze. |
| |
| Reference Range: |
| 0.7 - 1.4 mg/dL |
| |
| Clinical Utility: |
| Pyruvate, in conjunction with lactate determined from a blood specimen collected at the same time, is used to assess the L/P ratio. The L/P ratio is considered a helpful (not diagnostic) tool in the evaluation of patients with possible disorders of mitochondrial metabolism. Pyruvic acid levels alone have little clinical utility. |
| |
Print |
| Pyruvic Acid |
| |
| See Pyruvate |
|